Available data suggest that anti-LAG-3 as monotherapy may not be an optimal treatment and combination therapy notably with PD-1 inhibitors is widely studied especially since LAG-3 and PD-1 are co-expressed on tumor-infiltrating CD8+ T-cells as previously mentioned. This evidence concerns the gene LAG3 and neoplasm.